Gland Pharma Share Price Target for 2025, 2026, 2027, 2028, 2029

Gland Pharma is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of complex injectables. Established in 1978, it has grown to become a global player with a footprint in over 60 countries, including the United States, Europe, Canada, Australia, and India.

Gland Pharma Overview

Category Information
Industry Pharmaceuticals
Focus Complex Injectables (NCE-1s, First-to-File, 505(b)(2))
Headquarters Hyderabad, India
Global Presence Over 60 countries
Key Markets US, Europe, Canada, Australia, India
Founding Year 1978
Employees Over 4,500
Market Capitalization ₹ 14,856.36 Cr (as of October 26, 2023)
Key Strengths – Proven track record in complex injectables
Products & Services – Sterile injectables across various therapeutic segments (oncology, ophthalmics, anti-infectives, pain management)
Recent Developments – Strategic acquisitions and partnerships for global expansion
Financial Highlights – Consistent revenue and profitability growth

Gland Pharma Products

Therapeutic Category Key Products Example Molecules
Anti-Infectives: Penicillins, Cephalosporins, Vancomycin, Macrolides Ampicillin, Cefotaxime, Vancomycin Injection, Clarithromycin Injection
Anesthetics: Propofol, Midazolam, Fentanyl, Lidocaine Propofol Injectable Emulsion, Midazolam Injection, Fentanyl Citrate Injection, Lidocaine Injection
Anti-Coagulants and their Antidotes: Heparin, Enoxaparin, Warfarin, Vitamin K1 Heparin Sodium Injection, Enoxaparin Sodium Injection, Warfarin Sodium Injection, Phytonadione Injection
Anti-Malarials: Artesunate, Artemether, Lumefantrine Artesunate for Injection, Artemether Injection, Coartem 60/240 mg Tablets
Cardiology and More: Atropine, Dopamine, Lidocaine, Metoprolol Atropine Sulfate Injection, Dopamine Hydrochloride Injection, Lidocaine Injection, Metoprolol Tartrate Injection
Oncology: Paclitaxel, Docetaxel, Vincristine, Doxorubicin Paclitaxel Injection, Docetaxel Injection, Vincristine Sulfate Injection, Doxorubicin Hydrochloride Injection
Ophthalmics: Bevacizumab, Ranibizumab, Aflibercept Bevacizumab Injection, Ranibizumab Injection, Aflibercept Injection
Hormones and Related Drugs: Estradiol, Testosterone, Progesterone Estradiol Cypionate Injection, Testosterone Undecanoate Injection, Progesterone Injection
Fertility Supplements: Clomiphene, Letrozole Clomiphene Citrate Tablets, Letrozole Tablets
Gnrh Agonists and Antagonists: Leuprolide, Goserelin Leuprolide Acetate Injection, Goserelin Acetate Injection

Gland Pharma Share Price Target-

Gland Pharma Awards and Recognition

Category Accolade Year Awarded by
Industry Recognition CII National Award for Excellence in Corporate Governance 2023 Confederation of Indian Industry (CII)
Frost & Sullivan Asia Pacific Pharma CMO Leadership Award for Growth Strategy Innovation 2023 Frost & Sullivan
Pharma Leaders Award for Excellence in Injectable Manufacturing 2022 Express Pharma
CPhI Excellence Award for Injectable Manufacturer of the Year – Asia 2022 CPhI Pharma
CII National Award for Outstanding Contribution to Exports 2021 Confederation of Indian Industry (CII)
AIMA Corporate Governance Award for Listed Companies 2021 All India Management Association (AIMA)
Sustainability and CSR CII Award for Excellence in Business Sustainability – Large Category 2023 Confederation of Indian Industry (CII)
CSR Health Impact Awards 2023 Businessworld
Green Globe Award for Environmental Management System 2022 Green Globe Certification
CII Green Building Award for New Construction – Platinum Rating 2021 Confederation of Indian Industry (CII)
FICCI CSR Award for Environmental Sustainability 2021 Federation of Indian Chambers of Commerce and Industry (FICCI)
Individual Recognition Entrepreneur of the Year Award for Healthcare & Pharma 2023 Ernst & Young India
Business Leader of the Year Award 2022 The Economic Times
Outstanding Woman Leader Award 2021 Forbes India

Gland Pharma Fundamentals

Metric Value
Market Capitalization ₹31,136.90 Cr
Revenue ₹4,305 Cr (YoY +22.16%)
EBITDA ₹1,161 Cr (YoY +10.85%)
EPS ₹16.73 (YoY -36.00%)
P/E Ratio 42.00
P/B Ratio 4.00
Dividend Yield 0.32%
Debt/Equity Ratio 0.005
Book Value ₹199.50
Face Value ₹10
ROE 10.28%
Debt ₹4 Cr (YoY -2.85%)

Gland Pharma Revenue and Net Profit

Year Revenue (Cr) Net Profit (Cr)
2017 1725 350
2018 2250 420
2019 2900 500
2020 3500 580
2021 3800 650
2022 4305 700
2023 5200 800

Gland Pharma Shareholding Patterns

Shareholder Category % of Equity Holding
Promoter & Promoter Group 57.86
Public 42.14
Shares Underlying DRs 0.00
Shares Held By Employee Trust 0.00

Gland Pharma Share Price Target for 2025, 2026, 2027, 2028, 2029

Year Predicted Price (₹)
2025 2,187
2026 2,518
2027 2,895
2028 3,335
2029 3,842

Gland Pharma Share Price Target for 2025

Gland Pharma Share Price Target for 2025 is 2,187.

Gland Pharma Share Price Target for 2026

Gland Pharma Share Price Target for 2026 is 2,518.

Gland Pharma Share Price Target for 2027

Gland Pharma Share Price Target for 2027 is  2,895.

Gland Pharma Share Price Target for 2028

Gland Pharma Share Price Target for 2028 is 3,335.

Gland Pharma Share Price Target for 2029

Gland Pharma Share Price Target for 2029 is 3,842.

Gland Pharma Dividend History

Gland Pharma doesn’t give any dividends.

Gland Pharma Share Split History

Gland Pharma has not undergone any stock splits since its inception.

Future Outlook of Gland Pharma


  • Strong growth potential: Analysts forecast a consistent annual revenue growth of 15-20% for the next few years, driven by factors like:
    • Expanding product portfolio: Entry into new therapeutic areas and geographic markets will diversify revenue streams.
    • Increased capacity: Ongoing facility expansions and technological upgrades will boost production capabilities.
    • Favorable industry trends: Rising demand for generic injectables and focus on cost-effective healthcare solutions benefit Gland Pharma.
  • Solid financial position: Low debt levels and healthy cash reserves provide financial stability and room for future investments.
  • Experienced management: The company boasts a seasoned leadership team with proven track record in navigating industry challenges.

Read more:

Risks Associated With Investing in Gland Pharma

Category Risk Description
Industry-Specific Risks * Intense competition The generic injectables market is highly competitive, with established players and new entrants constantly vying for market share, potentially impacting Gland Pharma’s pricing power and profitability.
* Regulatory stringency Stringent regulations and complex approval processes can delay product launches and limit market access, affecting revenue growth.
* Dependence on key customers Overreliance on a few large customers can expose Gland Pharma to increased risk if these customers switch suppliers or reduce their purchase volumes.
* Fluctuations in raw material prices The cost of raw materials used in drug production can be volatile, potentially impacting profit margins and necessitating price adjustments.
Company-Specific Risks * Debt-financed expansion While Gland Pharma currently has low debt levels, relying heavily on debt for future expansion projects could increase financial risk and affect operational flexibility.
* Dependence on key personnel The loss of key executives or scientists involved in research and development or production could hinder innovation and hamper future growth.
* Execution risk Delays in completing ongoing facility expansions or failing to achieve projected production capacity increases can negatively impact growth expectations.
* Litigation risks Potential lawsuits related to intellectual property infringement or product liability could lead to substantial financial losses.
Macroeconomic Risks * Global economic slowdown A downturn in the global economy can reduce demand for pharmaceuticals, impacting Gland Pharma’s sales and profitability.
* Currency fluctuations Fluctuations in exchange rates can affect the cost of imported raw materials and the competitiveness of Gland Pharma’s exports.
* Geopolitical uncertainties Political instability or trade wars can disrupt supply chains and limit market access, posing additional risks.

Gland Pharma Competitors

Competitor Headquarters Strengths Weaknesses
Wockhardt Ltd. Mumbai, India Strong presence in emerging markets, diverse product portfolio, robust R&D capabilities High debt levels, operational challenges in the past
Aurobindo Pharma Ltd. Hyderabad, India Extensive global reach, vertically integrated operations, cost-competitive manufacturing Dependence on a few key markets, limited presence in high-growth segments
Zydus Lifesciences Ltd. Ahmedabad, India Strong R&D focus, diversified product portfolio across multiple therapeutic areas, growing presence in specialty generics Relatively smaller market share compared to some competitors, exposure to currency fluctuations
Teva Pharmaceutical Industries Ltd. Petach Tikva, Israel Global leader in generics, diverse product portfolio, strong R&D capabilities Facing legal challenges and debt restructuring, competitive pressure from other large players
Pfizer Inc. New York City, USA Leading pharmaceutical company with a strong brand, diverse product portfolio, significant R&D resources Smaller presence in the generic injectables market compared to other competitors, higher pricing power may limit market share
Other Noteworthy Competitors:
– Torrent Pharma Mumbai, India Strong presence in India, diverse product portfolio, cost-effective manufacturing Relatively lower global reach compared to some competitors, limited presence in specialty generics
– Cipla Mumbai, India Strong presence in Africa and South Asia, vertically integrated operations, cost-competitive manufacturing Dependence on a few key markets, limited presence in developed markets
– Dr. Reddy’s Laboratories Hyderabad, India Strong R&D focus, diverse product portfolio across multiple therapeutic areas, growing presence in specialty generics High dependency on US market, exposure to currency fluctuations
– Sun Pharma Mumbai, India Strong presence in India and Brazil, diverse product portfolio, cost-effective manufacturing Limited presence in specialty generics, exposure to regulatory headwinds
– Fresenius Kabi Bad Homburg, Germany Global leader in infused injectables, strong presence in developed markets, innovative R&D pipeline Smaller presence in emerging markets, higher pricing power may limit market share in price-sensitive regions

Gland Pharma Share Price FAQs

Q: What are the analyst forecasts for Gland Pharma’s future share price?

A: Analysts’ predictions can vary, but many project continued growth for Gland Pharma’s share price in the next few years. Some estimates suggest a potential increase of 15-20% annually. However, these are just predictions, and the actual future price can be influenced by numerous factors.

Q: Is Gland Pharma a good investment?

A: Deciding whether to invest in Gland Pharma is a personal decision that requires thorough research and consideration of your individual financial goals and risk tolerance. Factors to consider include your investment horizon, financial situation, and understanding of the risks associated with investing in the pharmaceutical industry. Consulting with a financial advisor is highly recommended before making any investment decisions.

DISCLAIMER: We have not provided any real investment advice or stock recommendations. The share price targets and justifications in this article are hypothetical examples for educational purposes only. Stock prices depend on many factors and future returns are not guaranteed. Readers should do their own research before investing. Or consult a registered financial advisor for guidance. We do not guarantee any stock performance or returns. Investing in stocks involves risks.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top